Results from the Phase III ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) trials showed that Abivax’s obefazimod demonstrated significant clinical remission in patients with ulcerative colitis.

Medically reviewed by Jay N. Yepuri, MD Inflammatory bowel disease (IBD) is a group of chronic (long-term) conditions that cause inflammation in the digestive tract, which includes the mouth, ...

A few of the Love Island 2025 cast members have been on TV before, and it turns out one of those is American bombshell and ...

Recurrent stomach pain in children isn’t always just gas. Know the warning signs, possible causes, and when it’s time to ...

About 2.7 million people in the U.S. live with inflammatory bowel diseases, which cause long-term inflammation in the ...

Burnout is among the reasons girls are dropping out of sports at two times the rate of boys. Gotham FC has been working to keep players in the game.

The latest announcement is out from Abivax SA Sponsored ADR ( (ABVX) ).

Mesheal Garrett, the suspect’s other son, said that she was attentive to his brother’s medical needs and had been seeking ...

Sara Levitt from Montreal, Canada, embraces life with an ostomy in a way that challenges expectations. Her ulcerative colitis and Crohn's disease journey led to years of pain and a diminished quality ...

Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the ...

Children’s charity ERIC supports families affected by bowel and bladder issues - but needs the public's help to continue ...